Article

Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs.

UCLA Department of Medicine, 10833 Le Conte Ave, CHS 37-131, Los Angeles, CA 90095, USA.
Blood (Impact Factor: 9.78). 10/2005; 106(6):2196-9. DOI: 10.1182/blood-2005-04-1766
Source: PubMed

ABSTRACT Hepcidin is the principal iron regulatory hormone and its overproduction contributes to anemia of inflammation (AI). In vitro, hepcidin binds to and induces the degradation of the exclusive iron exporter ferroportin. We explored the effects and distribution of synthetic hepcidin in the mouse. A single intraperitoneal injection of hepcidin caused a rapid fall of serum iron in a dose-dependent manner, with a 50-microg dose resulting in iron levels 80% lower than in control mice. The full effect was seen within only 1 hour, consistent with a blockade of iron export from tissue stores and from macrophages involved in iron recycling. Serum iron remained suppressed for more than 48 hours after injection. Using radiolabeled hepcidin, we demonstrated that the serum concentration of hepcidin at the 50-microg dose was 1.4 microM, consistent with the inhibitory concentration of 50% (IC50) of hepcidin measured in vitro. Radiolabeled hepcidin accumulated in the ferroportin-rich organs, liver, spleen, and proximal duodenum. Our study highlights the central role of the hepcidin-ferroportin interaction in iron homeostasis. The rapid and sustained action of a single dose of hepcidin makes it an appealing agent for the prevention of iron accumulation in hereditary hemochromatosis.

1 Bookmark
 · 
110 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study is to investigate the role of circulating prohepcidin and hepcidin, which are homeostatic regulators of iron me-tabolism and mediators of inflammation, in anemia associated with Behçet's disease (BD) and the differential diagnosis of healthy controls. Twenty patients with BD and twenty healthy controls were included in this prospective study. Laboratory tests including complete blood count, serum prohepcidin, hepcidin, iron, total iron binding capacity (TIBC), transferrin, ferritin, erythrocyte sedimen-tation rate (ESR) and C-reactive protein (CRP) were determined. Serum prohepcidin and hepcidin levels in patients with BD were sig-nificantly higher than healthy group. In the group with BD positive correlation was determined between the values of serum prohep-cidin, hepcidin, hemoglobin, total binding capacity and ferritine. Serum prohepcidin and hepcidin levels are closely associated with disease activity in patients and might play a role in the pathobiology of chronic disease anemia associated with patients with BD. ÖZET Behçet Hastal›¤› ile ‹liflkili Anemide Prohepsidin ve Hepsidinin Rolü Çal›flmam›z›n amac›; demir metabolizmas›nda homeostatik regülatör ve inflamasyon mediatörü olarak rol oynayan prohepsidin ve hepsidinin Behçet hastal›¤› (BH) ile iliflkili aneminin ay›r›c› tan›s›ndaki önemini araflt›rmakt›r. Yirmi Behçet hastas›, 20 sa¤l›k-l› eriflkin çal›flmaya al›nd›. Hastalardan tam kan, serum prohepsidin ve hepsidin, demir, total demir ba¤lama kapasitesi (TIBC), trans-ferin, ferritin, eritrosit sedimentasyon h›z› (ESR), c-reaktif protein (CRP) düzeyleri ölçüldü. Serum prohepsidin ve hepsidin düzeyleri, behçet hastal›¤› (BH) grubunda, sa¤l›kl› kontrol (SK) grubuna göre önemli düzeyde yüksek bulundu. BH grubunda, serum prohepsi-din ve hepsidin de¤erleri ile hemoglobin,demir ba¤lama kapasitesi, ferritin de¤erleri aras›nda korelasyon tespit edildi. Serum prohep-sidin ve hepsidin seviyelerinin Behçet hastal›¤›nda, hastal›k aktivitesiyle yak›n iliflkisi saptan›rken, oluflan kronik hastal›k anemisinin pa-tobiyolojisinde rol oynayabilece¤i düflünülmektedir.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anemia in cancer patients is often considered a side effect of cancer therapy; however, it may occur before any antineoplastic treatment (cancer-related anemia). This study aimed to evaluate cancer-related anemia prevalence of in a large cohort of cancer patients and whether inflammation and malnutrition were predictive of its development and severity. The present study included 888 patients with cancer at different sites between May 2011 and January 2014. Patients were assessed at diagnosis before any cancer treatment. The prevalence of anemia according to the main clinical factors (tumor site, stage and performance status) was analyzed. In each patient markers of inflammation, iron metabolism, malnutrition and oxidative stress as well as the modified Glasgow Prognostic Score, a combined index of malnutrition and inflammation, were assessed and their role in predicting hemoglobin level was evaluated. The percentage of anemic patients was 63% with the lowest hemoglobin levels in the most advanced cancer and compromised performance status. Hemoglobin differed by tumor site and was lowest in ovarian cancer patients. Hemoglobin negatively correlated with inflammatory markers, hepcidin, ferritin, erythropoietin and reactive oxygen species, and positively correlated with leptin, albumin, cholesterol and antioxidant enzymes. In multivariate analysis, stage, interleukin-6 and leptin were independent predictors of hemoglobin. Furthermore, hemoglobin was inversely dependent on modified Glasgow Prognostic Score. In conclusion, cancer-related anemia is a multifactorial problem with immune, nutritional and metabolic components that affect its severity. Only a detailed assessment of cancer-related anemia pathogenesis may enable clinicians to provide a safe and effective individualized treatment.
    Haematologica 09/2014; · 5.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Iron is an essential trace mineral that plays a number of important physiologic roles in humans, including oxygen transport, energy metabolism and neurotransmitter synthesis. Iron absorption by the proximal small bowel is a critical check point in the maintenance of whole-body iron levels as, unlike most other essential nutrients, no regulated excretory systems exist for iron in humans. Maintaining proper iron levels is critical to avoid the adverse physiological consequences of either low or high tissue iron concentrations, as commonly occurs in iron-deficiency anemia and hereditary hemochromatosis, respectively. Exquisite regulatory mechanisms have thus evolved to modulate how much iron is acquired from the diet. Systemic sensing of iron levels is accomplished by a network of molecules which regulate transcription of the HAMP gene in hepatocytes, thus modulating levels of the serum-borne, iron-regulatory hormone hepcidin. Hepcidin decreases intestinal iron absorption by binding to the iron exporter ferroportin 1 on the basolateral surface of duodenal enterocytes, causing its internalization and degradation. Mucosal regulation of iron transport also occurs during low-iron states, via transcriptional (by HIF2α) and post-transcriptional (by the iron-sensing IRP/IRE system) mechanisms. Recent studies demonstrated that these regulatory loops function in tandem to control expression or activity of key modulators of iron homeostasis. In health, body iron levels are maintained at appropriate levels; however, in several inherited disorders and in other pathophysiological states, iron sensing is perturbed and intestinal iron absorption is dysregulated. The iron-related phenotypes of these diseases exemplify the necessity of precisely regulating iron absorption to meet body demands.
    AJP Gastrointestinal and Liver Physiology 07/2014; · 3.74 Impact Factor

Preview

Download
3 Downloads